Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24211459 | 0.74 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL448145 | 0.69 | FDPS (0.32) | — | |
| SCHEMBL15202978 | 0.68 | LMNA (0.50) | — | |
| SCHEMBL2478796 | 0.67 | CA12 (0.35) | PIK3CDCA12CA1CA2CA9 | |
| SCHEMBL1276267 | 0.65 | FDPS (0.37) | CA12CA1CA2CA9 | |
| SCHEMBL25480754 | 0.64 | — | — | |
| SCHEMBL19909618 | 0.64 | PIK3CD (0.58) | PIK3CD | |
| SCHEMBL13359407 | 0.64 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL3461429 | 0.63 | MAPK1 (0.35) | CA12CA1CA2CA9 | |
| SCHEMBL19333307 | 0.63 | CYP1A2 (0.38) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126517-B1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3126517-B1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9598456-B2 | Modified cytosine polynucleotide oligomers and methods | CEPHEID (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598456-B2 | Modified cytosine polynucleotide oligomers and methods | CEPHEID (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598456-B2 | Modified cytosine polynucleotide oligomers and methods | CEPHEID (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3126517-A1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | Cepheid (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015153510-A1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015153510-A1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150275283-A1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150275283-A1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | CEPHEID (US) | 2015-10-01 | — | — | US | disclosed |
| EP-1261616-A2 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | Epoch Biosciences, Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1256589-A2 | Oligomers containing modified pyrimidines | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6380368-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | disclosed |
| WO-2001064958-A2 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENECS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| US-5830653-A | ABILITY TO INHIBIT GENE EXPRESSION | GILEAD SCIENCES, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5645985-A | USED FOR DIAGNOSIS TO DETECT VIRUSES OR DISEASED CONDITIONS | GILEAD SCIENCES, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0637965-A4 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. | GILEAD SCIENCES INC (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150275283-A1 | MODIFIED CYTOSINE POLYNUCLEOTIDE OLIGOMERS AND METHODS | POLN, POLI, POLRMT | PIK3CD 2710/4885CA12 3904/4885CA1 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.